| Literature DB >> 28620317 |
Eugenia Mata-Greenwood1, Dipali Goyal1,2, Ravi Goyal1,2.
Abstract
Background : Hypoxia inducible factor 1 alpha (HIF1A) is a master regulator of acute hypoxia; however, with chronic hypoxia, HIF1A levels return to the normoxic levels. Importantly, the genes that are involved in the cell survival and viability under chronic hypoxia are not known. Therefore, we tested the hypothesis that chronic hypoxia leads to the upregulation of a core group of genes with associated changes in the promoter DNA methylation that mediates the cell survival under hypoxia. Results : We examined the effect of chronic hypoxia (3 days; 0.5% oxygen) on human brain micro endothelial cells (HBMEC) viability and apoptosis. Hypoxia caused a significant reduction in cell viability and an increase in apoptosis. Next, we examined chronic hypoxia associated changes in transcriptome and genome-wide promoter methylation. The data obtained was compared with 16 other microarray studies on chronic hypoxia. Nine genes were altered in response to chronic hypoxia in all 17 studies. Interestingly, HIF1A was not altered with chronic hypoxia in any of the studies. Furthermore, we compared our data to three other studies that identified HIF-responsive genes by various approaches. Only two genes were found to be HIF dependent. We silenced each of these 9 genes using CRISPR/Cas9 system. Downregulation of EGLN3 significantly increased the cell death under chronic hypoxia, whereas downregulation of ERO1L, ENO2, adrenomedullin, and spag4 reduced the cell death under hypoxia. Conclusions : We provide a core group of genes that regulates cellular acclimatization under chronic hypoxic stress, and most of them are HIF independent.Entities:
Keywords: CpG islands; DNA methylation; HBMEC; epigenetic; hypoxic acclimatization
Year: 2017 PMID: 28620317 PMCID: PMC5450043 DOI: 10.3389/fphys.2017.00365
Source DB: PubMed Journal: Front Physiol ISSN: 1664-042X Impact factor: 4.566
Figure 1(A) Demonstrates the luminescence detected by real-time cell viability assay with a different number of cells/well with 24 h of normoxia and hypoxia exposure. (B) Demonstrates the changes in luminescence during 1 to 3 days of hypoxia exposure indicating the changes in cell viability and proliferation. N = 6 in each group. Data is presented as mean and standard error of mean. (C) Demonstrates a significant increase (P < 0.05; n = 6) in Caspase 3/7 activity in hypoxic cells as compared to that from normoxic cell. N = 6 in each group; *Denotes P < 0.05. Data is presented as mean and standard error of mean.
Figure 2Demonstrates the chief canonical pathways (A) and the chief functional pathways (B) identified by Ingenuity Pathway Analysis on genes altered by exposure to 0.5% oxygen (hypoxic) and 21% oxygen (normoxic) for 3 days. N = 6 in each group.
List of core genes altered in response to hypoxia in different microarray analysis.
| Days of hypoxia | 5 Days | 2 Days | 2 Days | 2 Days | 2 Days | 2 Days | 1 Day | 1 Day | 20 h | 16 h | 16 h | 12 h | 8 h | 8 h | 4 h | 2 h | 1 h |
| Cell type | HBMEC | CM | HUVEC | PVMEC | REC | ASMC | LEC | HUVEC | PBL | MCF4 | ASMC | HUVEC | HUVEC | HC | HUVEC | HUVEC | HUVEC |
| ADM | 4.39 | 1.67 | 4.72 | 2.92 | 4.92 | 5.99 | 3.53 | 13.42 | 1.88 | 60.26 | 1.77 | 10.82 | 9.75 | 24.44 | 5.93 | 3.46 | 1.5 |
| EGLN3 | 10.31 | 1.87 | 96.57 | 2.96 | 1.59 | 0.45 | 33.86 | 13.01 | 1.19 | 15.59 | 2.22 | 9.75 | 6.84 | NA | 3.95 | 1.46 | 0.98 |
| ENO2 | 2.74 | 1.95 | 4.72 | 2.68 | 3.62 | 1.85 | 5.91 | 17.64 | 1.23 | 22.20 | 2.91 | 8.45 | 13.37 | 1.08 | 3.31 | 0.8 | 0.94 |
| ERO1L | 2.83 | 2.22 | 2.24 | 1.64 | 2.41 | 4.31 | 2.13 | 2.63 | 1.78 | 6.62 | 7.85 | 1.72 | 1.34 | 2.47 | 1.54 | 0.98 | 0.73 |
| LOX | 5.72 | 16.96 | 2.46 | 1.64 | 3.50 | 1.72 | 3.89 | 12.31 | 0.90 | 19.06 | 1.36 | 5.75 | 2.96 | 1.13 | 1.84 | 1.06 | 0.94 |
| P4HA1 | 4.14 | 1.75 | 3.43 | 1.67 | 3.42 | 1.85 | 2.66 | 8.90 | 3.70 | 5.30 | 1.80 | 4.95 | 4.13 | 1.13 | 2.04 | 1.14 | 1.05 |
| PLOD2 | 2.67 | 2.43 | 1.83 | 1.94 | 2.10 | 3.46 | 2.51 | 3.65 | 0.91 | 2.62 | 2.97 | 2.56 | 2.72 | NA | 1.45 | 1.09 | 1.03 |
| SLC2A3 | 2.75 | 1.66 | 3.51 | 2.68 | 4.49 | 3.01 | 4.05 | 6.53 | 2 | 1.80 | 1.95 | 6.29 | 4.67 | 1.46 | 2.56 | 1.2 | 0.78 |
| SPAG4 | 2.66 | 1.72 | 4.80 | 1.51 | 2.99 | 2.41 | 1.65 | 23.63 | 0.87 | 22.99 | 1.51 | 12.50 | 7.75 | NA | 2.43 | 0.84 | 1.01 |
HMBEC, human brain microendothelial cells; CM, cardiomyocytes; HUVEC, human umbilical vein cells; PVMEC, pulmonary vein microendothelial cells; REC, renal endothelial cells; ASMC, aortic smooth muscle cells; LEC, lymphatic endothelial cells; PBL, peripheral blood lymphocytes; MCF4, breast carcinoma cell line; HC, primary hepatocytes; NR, Data not reported.
Enlist the presence (P) or absence (Ab) of the core hypoxic genes in the three studies on HIF1A target identification.
| ADM | Ab | Ab | P |
| EGLN3 | P | Ab | P |
| ENO2 | P | P | Ab |
| ERO1L | P | P | P |
| LOX | P | Ab | P |
| P4HA1 | P | Ab | P |
| PLOD2 | P | P | P |
| SLC2A3 | Ab | Ab | Ab |
| SPAG4 | P | Ab | Ab |
Shows the genes with correlative changes in mRNA levels and DNA methylation in response to hypoxia.
| MYBL2 | 0.18 | 1.52 |
| MFSD2A | 0.23 | 1.57 |
| NCAPG | 0.24 | 1.52 |
| C17orf53 | 0.25 | 1.58 |
| HELLS | 0.25 | 1.52 |
| MAD2L1 | 0.25 | 2.45 |
| KIFC1 | 0.25 | 1.58 |
| NOS3 | 0.26 | 1.58 |
| FAM111B | 0.32 | 1.73 |
| CIT | 0.33 | 1.55 |
| SFPQ | 0.37 | 1.51 |
| TXNDC11 | 0.37 | 1.51 |
| FSTL5 | 0.44 | 1.63 |
| ENSA | 0.48 | 1.58 |
| ZNF207 | 0.48 | 1.57 |
| PGBD4 | 0.48 | 1.51 |
| KPNA2 | 0.49 | 1.84 |
Figure 3Demonstrates the effect of 0.5% oxygen (hypoxic) and 21% oxygen (normoxic) for 3 days on normal cells and the cells with mutated genes by Crispr/Cas9. N = 6 in each group.
Showing % Viability in control vs. knockout cells following 0.5% hypoxia exposure.
| Control (WT) | 93.72 | 23.07 | 10.11 | 7.56 | ||
| ADM Knockout | 66.49 | 19.8 | 0.40 | 47.27 | 5.22 | 0.01 |
| EGLN3 Knockout | 0 | 0 | 0 | 0 | 0 | 0 |
| ENO2 Knockout | 50.1 | 13.49 | 0.15 | 35.6 | 6.71 | 0.04 |
| ERO1L Knockout | 82.72 | 13.65 | 0.70 | 36.92 | 6.34 | 0.03 |
| LOX Knockout | 67.75 | 13.42 | 0.37 | 18.9 | 2.92 | 0.39 |
| P4HA1 Knockout | 40.26 | 6.06 | 0.11 | 0.50 | 5.15 | 0.29 |
| PLOD2 Knockout | 40.49 | 4.29 | 0.01 | 3.50 | 3.90 | 0.69 |
| SLC2A3 Knockout | 171.51 | 11.79 | 0.02 | 22.04 | 11.62 | 0.41 |
| SPAG4 Knockout | 96.95 | 26.68 | 0.93 | 67.29 | 17.16 | 0.02 |
P-value, compared to control hypoxic cells at the same time point.
Oxygen concentration in various body tissues.
| Air | 21.0 | 160 | |
| Alveolus | 14.4 | 110 | |
| Arterial blood | 13.1 | 100 | |
| Venous blood | 5.3 | 40 | |
| Superficial skin | 1.1 | 8 | Wang et al., |
| Dermal papillae | 3.2 | 24 | Wang et al., |
| Sub-papillary plexus | 4.6 | 35 | Wang et al., |
| Brain regions | 0.55 to 8 | 4.1 to 60 | Panchision, |
| Brain – Duramater | 6.3 | 48 | Meixensberger et al., |
| 7–12 mm below duramater | 4.3 | 33 | Dings et al., |
| 17–22 mm below duramater | 3.4 | 26 | Dings et al., |
| 22–27 mm below duramater | 3.2 | 24 | Dings et al., |
| Kidney – Cortex | 6.6 | 50 | Brezis and Rosen, |
| Kidney medullary region | 1.3 to 2.6 | 10 to 20 | Brezis and Rosen, |
| Medial head of gastrocnemius | 3.8 | 28.9 | Bylund-Fellenius et al., |
| Vastas lateralis | 4.2 | 32 | Beerthuizen et al., |
| Biceps | 3.3 | 25 | Boekstegers et al., |
| Deltoid | 4.5 | 34 | Ikossi et al., |
| Tibialis anterior | 2.8 | 21 | Kiaer and Kristensen, |
| Bone marrow | 6.7 | 51 | Ishikawa and Ito, |
| Bone marrow | 7.2 | 55 | Harrison et al., |
| Human renal carcinoma | 1.3 | 9.6 | Lawrentschuk et al., |
| Human liver tumor | 0.8 | 6 | Vaupel et al., |
| Human primary brain tumors | 1.7 | 13 | Vaupel et al., |